You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

What is Bexsero?

Bexsero is a Meningococcal Group B vaccine.

Indication of Bexsero

Active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. The impact of invasive disease in different age groups as well as the variability of antigen epidemiology for group B strains in different geographical areas should be considered when vaccinating.

Safety

Bexsero is contraindicated in individuals with hypersensitivity to the active substance or to any of the excipients, or a life-threatening reaction after previous administration of a vaccine containing similar components.

Very common side effects ((these may affect more than 1 in 10 people) for Infants and children (up to 10 years of age) include; fever (≥38ºC), loss of appetite, tenderness or discomfort at the injection site (including severe injection site tenderness resulting in crying when injected limb is moved), painful joints, skin rash (children aged 12 to 23 months) (uncommon after booster), sleepiness, feeling irritable, unusual crying, vomiting, diarrhea and headache. For Adolescents (from 11 years of age) and adults Very common (these may affect more than 1 in 10 people) include; pain at the injection site resulting in inability to perform normal daily activity, painful muscles and joints, nausea, generally feeling unwell and headache

For further information on Bexsero please see the Bexsero summary of product characteristics (SPC).

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Bexsero is a registered trademark of the GlaxoSmithKline group of companies.